In Waning Days of the Current Administration, FDA Announces Red No. 3 Ban

January 16, 2025

Reading Time : 2 min

On January 15, 2025, FDA announced an order revoking the listings providing for the use of the color additive FD&C Red No. 3 in both foods (including dietary supplements) and ingested drugs. The order is in response to a 2022 petition filed by the Center for Science in the Public Interest, among other food safety and health advocates, which asserted that the additive induces cancer in male rats and urged the agency to revoke authorization. 

FD&C Red No. 3 (also referred to as erythrosine) was first listed in 1907 under the provisions of the Food and Drugs Act of 1906 (Food Inspection Decision 76), and later provisionally listed in 1960 as Red No. 3 for food, drug and cosmetic use.1  In 1969, FD&C Red No. 3 was permanently listed for use in food and ingested drugs and codified in §§74.303 and 74.1303. In 1990, the agency declined to extend the provisional listing of the additive for use in cosmetics and externally applied drugs based on evidence of thyroid neoplasia in rat carcinogenicity studies. However, the decision did not revoke the existing 1969 permanent listing for food and ingested drugs.

In the order, FDA states that based on the available data and information, the FD&C Red No. 3-induced thyroid tumors found in rats are “of limited relevance to humans.” However, citing section 721(b)(5)(B) of the Food, Drug and Cosmetic Act (the FD&C Act), often referred to as the Delaney Clause, the agency concluded that the findings of carcinogenicity render the color additive “unsafe” as a matter of law, regardless of the extent to which the experimental condition of the animal studies provides insight into the health effects of human consumption.2

The order further sets forth an effective date of January 15, 2027, for food and January 18, 2028, for ingested drugs. Subject to any forthcoming challenges to the order, the food industry and drug industry will need to move fairly quickly to assess potential formulation changes in advance of the respective effective dates.


1 See 25 Fed. Reg. 9759, (October 12, 1960).

2 See Section 721(b)(5)(B) of the FD&C Act (stating that a color additive shall be deemed unsafe for any use which will or may result in ingestion of all or part of such additive, if the additive is found by the Secretary to induce cancer when ingested by man or animal, or if it is found by the Secretary, after tests which are appropriate for the evaluation of the safety of additives for use in food, to induce cancer in man or animal.)

Share This Insight

Previous Entries

Eye on FDA

June 10, 2026

On June 2, 2026, the U.S. Food and Drug Administration (FDA) issued draft guidance on how drug and device companies may communicate health care economic information (HCEI) with payors (e.g., health insurance companies), formulary committees (e.g., pharmacy and therapeutics committees) and similar entities. The guidance, Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities – Questions and Answers, is now open for comment.

...

Read More

Eye on FDA

May 19, 2026

On May 12, 2026, the Food and Drug Administration (FDA) published a notice in the Federal Register requesting comment on the agency’s efforts related to drug repurposing to help address unmet medical needs. In this request for information (RFI), FDA is seeking input to identify potential new uses for FDA-approved drugs—such as a new indication or a new population—to help accelerate the availability of treatments for unmet medical needs. Stakeholders are encouraged to submit priority disease areas and potential candidates for drug repurposing, particularly in cases where there is a lack of commercial incentive to pursue labeling changes or a significant unmet need.

...

Read More

Eye on FDA

May 14, 2026

As medical chatbots proliferate, a new Pennsylvania lawsuit highlights a developing trend of states leading health artificial intelligence (AI) enforcement efforts, while the Food and Drug Administration (FDA) appears to be on the sidelines.

...

Read More

Eye on FDA

May 13, 2026

On May 12, 2026, the U.S. Food and Drug Administration (FDA) announced a major milestone in its approach to post-market oversight of chemicals in the food supply, finalizing a new proactive food chemical safety post-market assessment program and releasing two foundational papers: the “Enhanced Systematic Process for Post-Market Assessment of Chemicals in Food” and the “Tool for the Prioritization of Food Chemicals for Post-Market Assessment.”

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.